A recent study suggests that a drug approved for the treatment of seizures may also help treat Alzheimer's in people who do ...

Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 ...

Australia's Therapeutic Goods Administration (TGA) has said it won't approve Eisai and Biogen's Alzheimer's disease therapy ...

Potomac-based IGC Pharma Inc. Thursday announced enrollment of patients at the Baycrest Academy for Research and Education in ...

Alzheimer's disease might damage the brain in two distinct phases, a new study suggests. An early phase that occurs slowly ...

Annovis has limited cash reserves and faces challenges in financing further trials, making the future of Buntanetap uncertain ...

Researchers are investigating whether drugs currently used for diabetes and eye diseases could help to prevent or treat ...

Dementia Australia has expressed disappointment at the decision to reject for use in Australia a new drug claimed to slow the ...

On Thursday, Nexalin Technology, Inc (NASDAQ:NXL) (NASDAQ:NXLIW) announced results from a clinical trial of its Deep ...

Annovis faces financial challenges and questionable efficacy in Alzheimer's and Parkinson's trials, risking poor stock ...

A self-proclaimed Brazil-Italy collaboration enthusiast, researcher Laura Bolognesi created the B2AlzD2 Joint Lab at the ...